mutations predominate in non-small cell lung cancer (NSCLC) comprising 11-16% of lung adenocarcinomas, and 2-5% of pancreatic and colorectal adenocarcinomas (Cox, A.D. et al. Nat. Rev. Drug Discov. (2014) 13:828-51). Genomic studies across hundreds of cancer cell lines have demonstrated that cancer cells harboring KRAS mutations are highly dependent on KRAS function for cell growth and survival (McDonald, R. et al. Cell 170 (2017): 577-592). The role of mutant KRAS as an oncogenic driver is further supported by extensive in vivo experimental evidence showing mutant KRAS is required for early tumour onset and maintenance in animal models (Cox, A.D. et al. Nat Rev Drug Discov (2014) 13:828-51).

Taken together, these findings suggest that KRAS mutations play a critical role in human cancers; development of inhibitors targeting mutant KRAS may therefore be useful in the clinical treatment of diseases that are characterized by a KRAS mutation.

SUMMARY

The present disclosure provides, *inter alia*, a compound of Formula I:



(**I**)

or a pharmaceutically acceptable salt thereof, wherein constituent variables are defined herein.

In one aspect, there is provided a compound having Formula I:



or a pharmaceutically acceptable salt thereof, wherein:

Y is N or CH;

R^1 is selected from Cl, CH_3, CH_2F, CHF_2, and CF_3;

Cy^1 is selected from

 ,	 ,	 ,	 ,
Cy^1-a	Cy^1-b	Cy^1-c	Cy^1-d
 ,	 ,	 ,	 ,
Cy^1-e	Cy^1-f	Cy^1-g	Cy^1-h
 ,	 ,	 ,	 ,
Cy^1-i	Cy^1-j	Cy^1-k	Cy^1-l
 ,	 ,	 ,	 ,
Cy^1-m	Cy^1-n	Cy^1-o	Cy^1-p
 ,	 ,	 ,	and
Cy^1-q	Cy^1-r	Cy^1-s	
 ;			
Cy^1-t			

R^2 is selected from F and Cl;

R^3 is selected from

 ,	 ,	 ,	 and ;
R^3-a	R^3-b	R^3-c	R^3-d

and,

Cy^2 is selected from

 ,	 ,	 ,
Cy^2-a	Cy^2-b	Cy^2-c
 ,	 , and	 ;
Cy^2-d	Cy^2-e	Cy^2-f

provided that the compound of Formula I is other than,

2-((2S,4S)-4-(7-(2-chloro-3-methylphenyl)-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile,
2-((2S,4S)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-7-(2,3-dimethylphenyl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile, and
2-((2S,4S)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile.

In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

The present disclosure further provides methods of inhibiting KRAS activity, which comprises administering to an individual a compound of the disclosure, or a pharmaceutically acceptable salt thereof. The present disclosure also provides uses of the compounds described herein in the manufacture of a medicament for use in therapy. The present disclosure also provides the compounds described herein for use in therapy. In another aspect, there is provided a compound as defined herein or the composition as defined herein for use in therapy.

The present disclosure further provides methods of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided use of a compound as defined herein or the composition as defined herein in the manufacture of a medicament for inhibiting KRAS activity.

In another aspect, there is provided use of a compound as defined herein or the composition as defined herein in the manufacture of a medicament for treating a disease or disorder associated with inhibition of KRAS interaction.

In another aspect, there is provided use of a compound as defined herein or the composition as defined herein in the manufacture of a medicament for treating a disease or disorder associated with inhibiting a KRAS protein harboring a G12C mutation.

In another aspect, there is provided use of a compound as defined herein or the composition as defined herein in the manufacture of a medicament for treating a cancer.

What is claimed is:

1. A compound having Formula I:



(**I**)

or a pharmaceutically acceptable salt thereof, wherein:

Y is N or CH;

R^1 is selected from Cl, CH_3, CH_2F, CHF_2, and CF_3;

Cy^1 is selected from

			
Cy^1-a	Cy^1-b	Cy^1-c	Cy^1-d
			
Cy^1-e	Cy^1-f	Cy^1-g	Cy^1-h
			
Cy^1-i	Cy^1-j	Cy^1-k	Cy^1-l

 ,	 ,	 ,	 ,
Cy^1-m	Cy^1-n	Cy^1-o	Cy^1-p
 ,	 ,	 ,	and
Cy^1-q	Cy^1-r	Cy^1-s	
 ;			
Cy^1-t			

R^2 is selected from F and Cl;

R^3 is selected from

 ,	 ,	 ,	 and ;
R^3-a	R^3-b	R^3-c	R^3-d

and,

Cy^2 is selected from

 ,	 ,	 ,
Cy^2-a	Cy^2-b	Cy^2-c

 ,	 , and	 ;
Cy^2-d	Cy^2-e	Cy^2-f

provided that the compound of Formula I is other than,

2-((2S,4S)-4-(7-(2-chloro-3-methylphenyl)-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile,
2-((2S,4S)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-7-(2,3-dimethylphenyl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile, and
2-((2S,4S)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile.

2. The compound of claim 1, wherein the compound of Formula I is a compound of Formula II:



II

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from Cl and CH_3;

Cy^1 is selected from

 ,	 ,	 ,	 ,
Cy^1-c	Cy^1-l	Cy^1-m	Cy^1-n

 ,	 ,	 ,	 ,
Cy^1-o	Cy^1-p	Cy^1-q	Cy^1-r
 ,	and	 ;	
Cy^1-s		Cy^1-t	

R^3 is selected from

	and	 ;
R^3-a		R^3-d

and,

Cy^2 is selected from

 ,	 ,	 ,
Cy^2-b	Cy^2-d	Cy^2-e
and	 .	
	Cy^2-f	

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

Y is N or CH;

R^1 is selected from Cl, CH_3, CH_2F, CHF_2, and CF_3;

Cy^1 is selected from

 ,	 ,	 ,	 ,
Cy^1-a	Cy^1-b	Cy^1-c	Cy^1-d
 ,	 ,	 ,	 ,
Cy^1-e	Cy^1-f	Cy^1-g	Cy^1-h
 ,	 ,	and	 ;
Cy^1-i	Cy^1-j		Cy^1-k

R^2 is selected from F and Cl;

R^3 is selected from

 ,	 ,	and	 ;
R^3-a	R^3-b		R^3-c

and,

Cy^2 is selected from

 ,	 ,	 ,
Cy^2-a	Cy^2-b	Cy^2-c

 ,	 , and	 ;
Cy^2-d	Cy^2-e	Cy^2-f

provided that the compound of Formula I is other than

2-((2S,4S)-4-(7-(2-chloro-3-methylphenyl)-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile and
2-((2S,4S)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-7-(2,3-dimethylphenyl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile.

4. The compound of claim 1 or 3, or a pharmaceutically acceptable salt thereof, wherein

Y is N or CH;

R^1 is selected from Cl, CH_3, CH_2F, CHF_2, and CF_3;

Cy^1 is selected from

 ,	 ,	 ,	 ,
Cy^1-a	Cy^1-b	Cy^1-c	Cy^1-d
 ,	 ,	 ,	 ,
Cy^1-e	Cy^1-f	Cy^1-g	Cy^1-i
and	 ;	;	
	Cy^1-j		

R^2 is selected from F and Cl;

R^3 is selected from

 ,	 ,	and	 ;
R^3-a	R^3-b		R^3-c

and,

Cy^2 is selected from

 ,	 ,	 ,
Cy^2-a	Cy^2-b	Cy^2-c
 ,	 , and	 .
Cy^2-d	Cy^2-e	Cy^2-f

5. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein Y is CH.

6. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein Y is N.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein Cy^1 is selected from Cy^1-a, Cy^1-b, Cy^1-c, Cy^1-d, and Cy^1-e.

8. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein Cy^1 is selected from Cy^1-f, Cy^1-g, Cy^1-h, Cy^1-i, Cy^1-j, and Cy^1-k.

9. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein Cy^1 is selected from Cy^1-a and Cy^1-b.

10. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein Cy^1 is selected from Cy^1-l, Cy^1-m, Cy^1-n, Cy^1-o, Cy^1-p, Cy^1-q, Cy^1-r, Cy^1-s, and Cy^1-t .

11. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein Cy^1 is selected from Cy^1-c, Cy^1-m, Cy^1-n, Cy^1-o, Cy^1-p, Cy^1-q, Cy^1-r, Cy^1-s, and Cy^1-t.

12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from CH_3, CH_2F, CHF_2, and CF_3.

13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from CH_3 and CF_3.

14. The compound of any one of claims 1 and 3-13, or a pharmaceutically acceptable salt thereof, wherein R^2 is F.

15. The compound of any one of claims 1, and 3-13, or a pharmaceutically acceptable salt thereof, wherein R^2 is Cl.

16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from R^3-a and R^3-b.

17. The compound of any one of claims 1 and 3-15, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from R^3-b and R^3-c.

18. The compound of any one of claims 1 and 3-17, or a pharmaceutically acceptable salt thereof, wherein Cy^2 is selected from Cy^2-a, Cy^2-b, and Cy^2-d.

19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein Cy^2 is selected from Cy^2-a and Cy^2-b.

20. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein Cy^2 is selected from Cy^2-b and Cy^2-d.

21. The compound of claim 1 or 3, wherein the compound of Formula I is selected from 2-((2*S*,4*S*)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-7-(5-fluoroquinolin-8-yl)-8-(trifluoromethyl)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-7-(2-methoxy-3-methylphenyl)-8-(trifluoromethyl)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(7-(3-chloro-2-methoxyphenyl)-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-8-(trifluoromethyl)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(6-fluoro-7-(5-fluoroquinolin-8-yl)-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-8-(trifluoromethyl)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile;

1-(4-(6-fluoro-7-(5-fluoroquinolin-8-yl)-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-8-(trifluoromethyl)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)piperidin-1-yl)prop-2-en-1-one;

2-((2*S*,4*S*)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-7-(2,3-dimethylphenyl)-6-fluoro-8-methyl-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(6-fluoro-8-methyl-7-(1-methyl-1*H*-indazol-6-yl)-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(6-fluoro-8-methyl-7-(6-methylpyridin-3-yl)-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(6-fluoro-8-methyl-7-(1-methyl-1*H*-indazol-3-yl)-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(6-fluoro-7-(4-fluorophenyl)-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile;

8-(1-(1-acryloylpiperidin-4-yl)-6-fluoro-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-7-yl)-1-naphthonitrile;

2-((2S,4S)-4-(7-(2-chloro-3-methylphenyl)-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-8-methyl-1H-imidazo[4,5-c]quinolin-1-yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(7-(2-chloro-3-methylphenyl)-6-fluoro-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

8-(1-((2*R*,4*S*)-1-acryloyl-2-methylpiperidin-4-yl)-6-fluoro-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-7-yl)-1-naphthonitrile;

2-((2*S*,4*S*)-4-(7-(5,6-dimethyl-1*H*-indazol-4-yl)-4-(3-(ethyl(methyl)amino)azetidin-1-yl)-6-fluoro-8-methyl-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

8-(6-fluoro-1-(1-((*E*)-4-fluorobut-2-enoyl)piperidin-4-yl)-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-7-yl)-1-naphthonitrile;

8-(1-((2*S*,4*S*)-2-(cyanomethyl)-1-(2-fluoroacryloyl)piperidin-4-yl)-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-8-methyl-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-7-yl)-1-naphthonitrile;

2-((2*S*,4*S*)-4-(6,8-dichloro-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-7-(5-fluoroquinolin-8-yl)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2*S*,4*S*)-4-(6,8-dichloro-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-7-(5-fluoroquinolin-8-yl)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile; and

2-((2*S*,4*S*)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-7-(5-fluoroquinolin-8-yl)-8-(trifluoromethyl)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-1-yl)-1-((*E*)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile;

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1, wherein the compound of Formula I is selected from:

2-((2S,4S)-4-(6-fluoro-7-(4-fluoroisoquinolin-1-yl)-8-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2S,4S)-4-(6-fluoro-7-(4-fluoroisoquinolin-1-yl)-8-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

2-((2S,4S)-4-(6-fluoro-8-methyl-7-(3-methylisoquinolin-4-yl)-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

2-((2S,4S)-4-(6-fluoro-8-methyl-7-(3-methylisoquinolin-4-yl)-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2S,4S)-4-(6-fluoro-7-(7-fluoro-2-methylquinolin-8-yl)-8-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

2-((2S,4S)-4-(6-fluoro-8-methyl-7-(1-methylisoquinolin-4-yl)-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-((E)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile;

2-((2S,4S)-4-(6-fluoro-7-(7-fluoroquinolin-8-yl)-8-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

2-(4-(1-((2R,4S)-1-acryloyl-2-methylpiperidin-4-yl)-6-fluoro-8-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-7-yl)-1-methyl-1H-indazol-3-yl)acetonitrile;

2-((2S,4S)-4-(4-(3-(ethyl(methyl)amino)-3-methylazetidin-1-yl)-6-fluoro-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

2-((2S,4S)-4-(7-(5,6-dimethyl-1H-indazol-4-yl)-4-(3-(ethyl(methyl)amino)-3-methylazetidin-1-yl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

2-(4-(1-((2*R*,4*S*)-1-acryloyl-2-methylpiperidin-4-yl)-6-fluoro-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-7-yl)-1-methyl-1*H*-indol-3-yl)acetonitrile;

2-(4-(1-(1-acryloylpiperidin-4-yl)-6-fluoro-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-[1,2,3]triazolo[4,5-*c*]quinolin-7-yl)-1-methyl-1*H*-indol-3-yl)acetonitrile;

2-((2S,4S)-4-(8-chloro-7-(5,6-dimethyl-1H-indazol-4-yl)-4-(3-(ethyl(methyl)amino)-3-methylazetidin-1-yl)-6-fluoro-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

2-((2S,4S)-4-(6-fluoro-7-(2-fluoro-6-methoxyphenyl)-8-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile; and

2-((2S,4S)-4-(8-chloro-4-(3-(ethyl(methyl)amino)-3-methylazetidin-1-yl)-6-fluoro-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-1H-[1,2,3]triazolo[4,5-c]quinolin-1-yl)-1-(2-fluoroacryloyl)piperidin-2-yl)acetonitrile;

or a pharmaceutically acceptable salt thereof.

23. A pharmaceutical composition comprising a compound of any one of claims 1-22, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

24. Use of a compound of any one of claims 1-22, or the composition of claim 23 in the manufacture of a medicament for inhibiting KRAS activity.

25. The use of claim 24, wherein the medicament is to be administered to a patient.

26. Use of a compound of any one of claims 1-22, or the composition of claim 23 in the manufacture of a medicament for treating a disease or disorder associated with inhibition of KRAS interaction.

27. Use of a compound of any one of claims 1-22, or the composition of claim 23 in the manufacture of a medicament for treating a disease or disorder associated with inhibiting a KRAS protein harboring a G12C mutation.

28. Use of a compound of any one of claims 1-22, or the composition of claim 23 in the manufacture of a medicament for treating a cancer.

29. The use of claim 28, wherein the cancer is selected from carcinomas, hematological cancers, sarcomas, and glioblastoma.

30. The use of claim 29, wherein the hematological cancer is selected from myeloproliferative neoplasms, myelodysplastic syndrome, chronic and juvenile myelomonocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, and multiple myeloma.

31. The use of claim 29, wherein the carcinomas is selected from pancreatic, colorectal, lung, bladder, gastric, esophageal, breast, head and neck, cervical, skin, and thyroid.

32. The use of claim 27, wherein the disease or disorder is an immunological or inflammatory disorder.

33. The use of claim 32, wherein the immunological or inflammatory disorder is Ras-associated lymphoproliferative disorder and juvenile myelomonocytic leukemia caused by somatic mutations of KRAS.

34. A compound of any one of claims 1-22, or the composition of claim 23 for use in therapy.